US Patent

US9629861 — Compositions and methods for treating bacterial infections using ceftaroline

Formulation · Assigned to Forest Laboratories Holdings ULC · Expires 2030-09-21 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compositions containing ceftaroline or a prodrug thereof, such as ceftaroline fosamil, for treating bacterial infections.

USPTO Abstract

The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).

Drugs covered by this patent

Patent Metadata

Patent number
US9629861
Jurisdiction
US
Classification
Formulation
Expires
2030-09-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Forest Laboratories Holdings ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.